CBX

 Kanghong Pharma has initiated the phase 1 clinical trial of KH801, a humanized  anti-CD24 antibody, in patients with solid tumors. The China NMPA cleared the IND application of KH801 in March 2024. The first-in-human study was estimated to enroll 17-42 patients with 7 dose groups. Targeting the CD24-Siglec10 Axis KH801 KH801 eliminates tumor cells through Fc-mediated immune response and by inhibiting CD24/Siglec10 signaling in both. CD24, a small membrane protein heavily glycosylated and anchored by GPI, interacts with Siglec-10 on TAMs (Tumor-Associated Macrophages) to act as a 'don't eat me' signal, aiding tumor cells in evading macrophage engulfment. CD24 is prevalent across various solid tumors. In 2021, Kanghong applied for a patent () WO2023104066  for using the anti-CD24 antibody or an antigen-binding fragment to treat tumors or immune diseases.  Kanghong presented the preclinical study results at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Mee